1291087-14-3

1291087-14-3 structure
1291087-14-3 structure
  • Name: AMG 837 hemicalcium salt
  • Chemical Name: AMG 837
  • CAS Number: 1291087-14-3
  • Molecular Formula: C26H21F3O3.1/2Ca
  • Molecular Weight: 914.939
  • Catalog: Signaling Pathways GPCR/G Protein GPR40
  • Create Date: 2018-06-21 14:08:14
  • Modify Date: 2025-09-01 01:44:53
  • AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of GPR40/FFA1, inhibits specific [3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents[1][2][3].

Name AMG 837
Synonyms Calcium bis[(3S)-3-(4-{[4'-(trifluoromethyl)-3-biphenylyl]methoxy}phenyl)-4-hexynoate]
Benzenepropanoic acid, β-1-propyn-1-yl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]-, calcium salt, (βS)- (2:1)
Description AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of GPR40/FFA1, inhibits specific [3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents[1][2][3].
Related Catalog
Target

pIC50: 8.13 (FFA1)[3]

In Vitro AMG 837 (1 nM-10 μM) stimulates insulin secretion in a glucose-dependent manner with an EC50 of 142±20 nM on islets isolated from mice[1]. AMG 837 stimulates Ca2+ flux with the EC50s of 13.5, 22.6 and 31.7 nM for human, mouse and rat receptors in CHO cells, respectively[1].
In Vivo AMG 837 (0.03-0.3 mg/kg; a single p.o.) improves glucose tolerance and enhances insulin secretion in Sprague-Dawley rats[1]. AMG 837 (0.5 mg/kg; p.o.) displays excellent oral bioavailability (%F = 84) and a total plasma Cmax of 1.4 µM[1]. AMG 837 (0.03-0.3 mg/kg; p.o. once daily for 21 days) reduces glucose levels and increases insulin levels following glucose challenge in vivo[1]. Animal Model: 8-week old Sprague-Dawley rats[1] Dosage: 0.03, 0.1, 0.3 mg/kg Administration: A single p.o. administration Result: Reduced the post-prandial glucose with the half-maximal dose of 0.05 mg/kg. Animal Model: 8-week old Zucker Fatty Rats[1] Dosage: 0.03, 0.1, 0.3 mg/kg Administration: Oral gavage once daily for 21 days Result: Decreased glucose AUC values during the glucose tolerance test (GTT) to 7%, 15%, and 25% at 0.03, 0.1 and 0.3 mg/kg, respectively. Increased insulin levels in the mid- and high-dose groups. Not affected body weights during the 21-day treatment.
References

[1]. Daniel CHL, et, al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One. 2011; 6(11): e27270.

[2]. Houze JB, et, al. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett. 2012 Jan 15; 22(2): 1267-70.

[3]. Daniel CHL, et, al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. 2012 Nov;82(5):843-59.

Molecular Formula C26H21F3O3.1/2Ca
Molecular Weight 914.939
Exact Mass 914.235474
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.